The proportion of patients who experienced pCR was numerically higher among those who had PD-L1+ tumors (PD-L1-expressing tumor-infiltrating immune cells (IC) ≥ 1% IC, n = 172) versus those with PD-L1− tumors (<1% IC, n = 338). Here, CD274 is linked to neoplasm.